Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for ENDRA Life Sciences Inc. (NDRA : NSDQ)

• Company Description    ENDRA Life Sciences Inc. is a developer of enhanced ultrasound technologies. ENDRA Life Sciences Inc. is based in Ann Arbor, United States. Number of Employees: 21

• Price / Volume Information    Yesterday's Closing Price: $4.74 Daily Weekly Monthly 20 Day Moving Average: 26,086 shares Shares Outstanding: 0.75 (millions) Market Capitalization: $3.57 (millions) Beta: -0.14 52 Week High: $14.63 52 Week Low: $2.90 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 6.76% 4.88% 12 Week 47.66% 34.13% Year To Date -24.28% -34.25%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3600 GREEN COURT SUITE 350 - ANN ARBOR,MI 48105 USA ph: 734-335-0468 fax: - ybriggs@allianceadvisors.com http://www.endrainc.com

• General Corporate Information    Officers Alexander Tokman - Chief Executive Officer and Chairman Richard Jacroux - Chief Financial Officer Louis J. Basenese - Director Anthony DiGiandomenico - Director Michael Harsh - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED INSTRUMENTS Sector: Medical CUSIP: 29273B500 SIC: 3845 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/21/25 Share - Related Items Shares Outstanding: 0.75 Most Recent Split Date: 11.00 (0.03:1) Beta: -0.14 Market Capitalization: $3.57 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-2.67 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-10.33 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/21/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.42 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 98.78% vs. Previous Quarter: 33.98% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -194.14 03/31/25 - -140.96 12/31/24 - -152.77 ROA 06/30/25 - -127.89 03/31/25 - -106.14 12/31/24 - -117.85 Current Ratio 06/30/25 - 3.21 03/31/25 - 3.85 12/31/24 - 5.68 Quick Ratio 06/30/25 - 3.21 03/31/25 - 3.85 12/31/24 - 5.68 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - 1.96 03/31/25 - 3.12 12/31/24 - 4.77 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©